DB05056ExperimentalSmall molecule
EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders. GC is a glycolipid that has been shown by Enzo scientists and collaborators to...
- Primary indication
- Investigated for use/treatment in crohn's disease, hepatitis (unspecified), and liver disease.Curator reviewed
- Code names
- EGS21
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with EGS21, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account